Cidara Therapeutics Inc (CDTX) USD0.0001

Sell:$48.20Buy:$52.80$0.35 (0.68%)

Prices delayed by at least 15 minutes
Sell:$48.20
Buy:$52.80
Change:$0.35 (0.68%)
Prices delayed by at least 15 minutes
Sell:$48.20
Buy:$52.80
Change:$0.35 (0.68%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.

Key people

Jeffrey L. Stein
President, Chief Executive Officer, Director
Frank L. Karbe
Chief Financial Officer
Shane Ward
Chief Operating Officer, Chief Legal Officer, Company Secretary
Daniel D. Burgess
Independent Chairman of the Board
Bonnie Bassler
Independent Director
Carin Canale-Theakston
Independent Director
James Merson
Independent Director
Chrysa Mineo
Independent Director
Click to see more

Key facts

  • EPIC
    CDTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1717572069
  • Market cap
    $1.03bn
  • Employees
    69
  • Shares in issue
    20.16m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.